{"schema_version":"secwatch.filing_event.v1","accession":"0000318154-23-000011","form_type":"8-K","ticker":"AMGN","cik":"0000318154","company_name":"AMGEN INC","filed_at":"2023-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.599291+00:00","generated_at":"2026-06-20T05:48:40.913826+00:00","sec_items":["1.01","2.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amgen posts flat Q4 revenue $6.8B, GAAP EPS down 11%; FTC extends HSR review for Horizon deal","bullets":["GAAP EPS $3.00 (down 11% YoY); non-GAAP EPS $4.09 (down 7% YoY).","Total revenue $6.8B unchanged; product sales +4% with 10% volume growth.","Full year 2022 revenue $26.3B (+1%), GAAP EPS $12.11, non-GAAP EPS $17.69.","FTC issued Second Request for Horizon acquisition, extending HSR waiting period 30 days after compliance.","2023 guidance provided excluding Horizon; free cash flow $8.8B for full year 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000318154-23-000011","json":"https://secwatch.observer/filing/0000318154-23-000011.json","markdown":"https://secwatch.observer/filing/0000318154-23-000011.md","text":"https://secwatch.observer/filing/0000318154-23-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318154/000031815423000011/0000318154-23-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318154/000031815423000011/amgn-20230130.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T05:48:40.913826+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"08a9976dd5bb7ef2de2199a39a555cb76f5956a0","claim":"AMGEN INC reported the three months ended December 31, 2022 results: revenue $6.8 billion, EPS $3.00.","evidence_excerpt":"For the fourth quarter, total revenues were $6.8 billion, largely unchanged from Q4 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318154/000031815423000011/0000318154-23-000011-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"Revenue","value":"$6.8 billion"},{"label":"EPS","value":"$3.00"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"d654ef2134b6af414b51d888d4fd1b1104081047","claim":"AMGEN INC reported the year ended December 31, 2022 results: revenue $26.3 billion, EPS $12.11.","evidence_excerpt":"For the full year, total revenues increased 1% to $26.3 billion","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318154/000031815423000011/0000318154-23-000011-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$26.3 billion"},{"label":"EPS","value":"$12.11"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ed954b277ba4604cc59b3f22b85ab5bfb6853e7e","claim":"AMGEN INC updated its 2023 guidance (initiated).","evidence_excerpt":"AMGEN ALSO PROVIDES 2023 GUIDANCE EXCLUDING ANY CONTRIBUTION FROM THE ANNOUNCED ACQUISITION OF HORIZON THERAPEUTICS","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318154/000031815423000011/0000318154-23-000011-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}